Neopharm, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded as renamed to Insys Therapeutics, Inc. (2019)
2
Ending by 2030
Aug 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 11, 2027The maintenance fee for Antibodies against glucagon receptor and their use (US 9,102,732) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Cosmetic composition comprising amide-based compound (US 11,744,791) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,809,390 | Compound accelerating secretion of human-derived anti-microbial peptide, method for preparing same, and composition having same as active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 9,102,732 | Antibodies against glucagon receptor and their use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,957,102 | Heterocyclic compound as protein kinase inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,512,220 | Antibodies against angiopoietins 1 and 2, and their use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,744,243 | Composition of external application to skin In force · From the USPTO record | In force | From the USPTO record | |
| US 9,867,776 | Transdermal drug delivery system having multi-lamellar emulsion structure In force · From the USPTO record | In force | From the USPTO record | |
| US 9,796,665 | Ceramide derivatives having agonistic effects on epidermal cannabinoid receptors, and pharmaceutical or cosmetic composition containing same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,783,489 | Pseudo ceramide compound, and pharmaceutical composition and cosmetic composition comprising same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,016,351 | Composition for promoting hair growth or preventing hair loss In force · From the USPTO record | In force | From the USPTO record | |
| US 10,695,275 | Anti-aging composition In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 18: 10 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 abandoned · 23 no status recorded